CA3052503A1 - Methods of treating influenza - Google Patents
Methods of treating influenza Download PDFInfo
- Publication number
- CA3052503A1 CA3052503A1 CA3052503A CA3052503A CA3052503A1 CA 3052503 A1 CA3052503 A1 CA 3052503A1 CA 3052503 A CA3052503 A CA 3052503A CA 3052503 A CA3052503 A CA 3052503A CA 3052503 A1 CA3052503 A1 CA 3052503A1
- Authority
- CA
- Canada
- Prior art keywords
- influenza
- virus
- influenza virus
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017900385A AU2017900385A0 (en) | 2017-02-08 | Methods of treating influenza | |
| AU2017900385 | 2017-02-08 | ||
| PCT/AU2018/050085 WO2018145148A1 (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3052503A1 true CA3052503A1 (en) | 2018-08-16 |
Family
ID=63106827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3052503A Pending CA3052503A1 (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10918623B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3579833B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7019727B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102607599B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110325187B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018218179B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019016316A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3052503A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2910136T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX387115B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2769317C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201907034PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018145148A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| PL3349758T3 (pl) | 2015-09-16 | 2022-09-12 | Gilead Sciences, Inc. | Sposoby leczenia zakażeń wirusami arenaviridae |
| KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772A1 (en) | 2021-05-26 | 2024-04-10 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2023092180A1 (en) * | 2021-11-24 | 2023-06-01 | Biotron Limited | Methods of treating sars-cov-2 infection |
| CA3243944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | COMPOUNDS AND METHODS OF TREATMENT FOR VIRAL INFECTIONS |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US20230382940A1 (en) | 2022-03-03 | 2023-11-30 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| PE20250419A1 (es) | 2022-03-03 | 2025-02-14 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos |
| JP2025519390A (ja) | 2022-06-06 | 2025-06-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法 |
| EP4547334A1 (en) | 2022-06-29 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240043466A1 (en) | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4665737A1 (en) | 2023-02-16 | 2025-12-24 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2025049699A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250084088A1 (en) | 2023-08-31 | 2025-03-13 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025054278A1 (en) | 2023-09-06 | 2025-03-13 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| WO2025072641A1 (en) | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2826770T (pt) | 2005-06-24 | 2018-12-18 | Biotron Ltd | Compostos acilguanidinas com atividade antiviral |
| BRPI0814737B8 (pt) * | 2007-08-03 | 2021-05-25 | Biotron Ltd | composição para o tratamento de hcv, e, uso de uma composição |
| KR101369584B1 (ko) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | 페닐-이속사졸 유도체 및 그의 제조방법 |
| KR20170063512A (ko) * | 2014-07-07 | 2017-06-08 | 프로필락시스 엘엘씨 | 바이러스 예방 치료 방법 및 사전-노출 예방 키트 |
| CN110870864B (zh) | 2018-08-29 | 2021-09-24 | 复旦大学 | 马来酸卡比沙明在制备抗流感病毒药物中的应用 |
-
2018
- 2018-02-07 ES ES18751710T patent/ES2910136T3/es active Active
- 2018-02-07 CA CA3052503A patent/CA3052503A1/en active Pending
- 2018-02-07 JP JP2019563650A patent/JP7019727B2/ja active Active
- 2018-02-07 RU RU2019126746A patent/RU2769317C2/ru active
- 2018-02-07 CN CN201880010492.9A patent/CN110325187B/zh active Active
- 2018-02-07 AU AU2018218179A patent/AU2018218179B2/en active Active
- 2018-02-07 WO PCT/AU2018/050085 patent/WO2018145148A1/en not_active Ceased
- 2018-02-07 EP EP18751710.7A patent/EP3579833B1/en active Active
- 2018-02-07 SG SG11201907034PA patent/SG11201907034PA/en unknown
- 2018-02-07 KR KR1020197024919A patent/KR102607599B1/ko active Active
- 2018-02-07 US US16/483,958 patent/US10918623B2/en active Active
- 2018-02-07 BR BR112019016316-6A patent/BR112019016316A2/pt not_active Application Discontinuation
- 2018-02-07 MX MX2019009443A patent/MX387115B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2769317C2 (ru) | 2022-03-30 |
| AU2018218179A1 (en) | 2019-08-22 |
| RU2019126746A3 (cg-RX-API-DMAC7.html) | 2021-05-28 |
| RU2019126746A (ru) | 2021-03-09 |
| MX2019009443A (es) | 2019-12-16 |
| NZ755900A (en) | 2025-03-28 |
| JP2020506243A (ja) | 2020-02-27 |
| CN110325187B (zh) | 2022-09-30 |
| US20200093796A1 (en) | 2020-03-26 |
| EP3579833A4 (en) | 2021-01-13 |
| JP7019727B2 (ja) | 2022-02-15 |
| EP3579833B1 (en) | 2022-01-05 |
| BR112019016316A2 (pt) | 2020-03-31 |
| MX387115B (es) | 2025-03-19 |
| CN110325187A (zh) | 2019-10-11 |
| WO2018145148A1 (en) | 2018-08-16 |
| KR102607599B1 (ko) | 2023-11-28 |
| EP3579833A1 (en) | 2019-12-18 |
| SG11201907034PA (en) | 2019-08-27 |
| AU2018218179B2 (en) | 2023-05-04 |
| ES2910136T3 (es) | 2022-05-11 |
| US10918623B2 (en) | 2021-02-16 |
| KR20190112051A (ko) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018218179B2 (en) | Methods of treating influenza | |
| Wu et al. | Progress of small molecular inhibitors in the development of anti-influenza virus agents | |
| Tarbet et al. | Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice | |
| WO2017223231A1 (en) | (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza | |
| Hussein et al. | Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus | |
| WO2020241759A1 (ja) | インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤 | |
| WO2012142492A2 (en) | Methods for inhibiting virus replication | |
| Zhang et al. | Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus | |
| US10221152B2 (en) | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | |
| EP3934653B1 (en) | Azelastine as antiviral treatment | |
| CN110870864B (zh) | 马来酸卡比沙明在制备抗流感病毒药物中的应用 | |
| CN118574614A (zh) | 治疗sars-cov-2感染的方法 | |
| HK40017310A (en) | Methods of treating influenza | |
| HK40017310B (en) | Methods of treating influenza | |
| Pakvis | Current trends of hemagglutinin and M2 protein inhibition for the treatment of influenza using antivirals | |
| TWI530284B (zh) | 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220919 |
|
| EEER | Examination request |
Effective date: 20220919 |
|
| EEER | Examination request |
Effective date: 20220919 |
|
| EEER | Examination request |
Effective date: 20220919 |
|
| EEER | Examination request |
Effective date: 20220919 |